Neuroprotective Evaluation of Asiatic Acid in Preclinical Stroke
Neuroprotective Evaluation of Asiatic Acid in Preclinical Stroke
批准号:
7846748
负责人:
ARSHAD MAJID
金额:
$18.81万
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-06-01 至 2011-05-31
关键词:
Adverse effectsAftercareAnti-Inflammatory AgentsAnti-inflammatoryAntioxidantsApoptosisCause of DeathCell DeathCerebral IschemiaCerebrumDataDoseDrug KineticsEvaluationEventFDA approvedFree RadicalsGlutamatesGoalsHospitalsHourHumanInfarctionInflammationInjuryInterruptionLeadMatrix MetalloproteinasesModelingMusNeuroprotective AgentsPathway interactionsPatientsPerfusionPharmaceutical PreparationsPlantsProcessPropertyPublishingRattusRoleSafetyStrokeSymptomsTestingTherapeuticTimeTranslationsUnited Statesasiatic acidbasedisabilityexcitotoxicityinnovationintravenous administrationneuroprotectionpre-clinicalpreclinical studypublic health relevanceresearch clinical testingresponsestroke therapy
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant):
Cellular damage during stroke occurs via multiple and diverse pathways. There are considerable data implicating the pathways of secondary inflammation, enhanced matrix metalloproteinase activity, excitotoxicity, apoptosis, free radical injury, and microglial activation. An "ideal" neuroprotectant should favorably influence multiple pathways, should be safe and well tolerated, and should have a long therapeutic time window. Asiatic acid is a plant-derived compound that has been shown to favorably influence multiple deleterious pathways that are activated in stroke through its anti- glutamate, anti-oxidant and anti-inflammatory properties. Our preliminary studies in mice subjected to permanent focal cerebral ischemia suggest that pre-treatment and post-treatment with asiatic acid significantly reduces infarct size without any obvious toxic side effects. Based on this and other published data, asiatic acid could emerge as a candidate for testing as a stroke therapy. However, before clinical testing can take place, rigorous and extensive preclinical pharmacokinetic, safety and efficacy data is required. These data are not available at this time. The goal of this proposal is to generate preclinical pharmacokinetic, efficacy and safety data for the use of asiatic acid as a neuroprotective therapy in stroke. These data will be used to plan more detailed preclinical studies that will allow translation to human testing.
PUBLIC HEALTH RELEVANCE:
Stroke is one of the leading causes of death and disability in the United States. The only approved FDA therapy must be administered within three hours of symptom onset but most stroke victims are not eligible for this treatment because they arrive in hospital too late. The goal of this project is to evaluate pre-clinically, a safe, innovative and promising natural drug called asiatic acid, because it has produced excellent results in early preclinical stroke studies and has the potential to benefit many more stroke patients.
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
DOI:
10.1161/strokeaha.111.639427
发表时间:
2012-06
期刊:
Stroke
影响因子:
8.3
作者:
[Lee KY, Bae ON, Serfozo K, Hejabian S, Moussa A, Reeves M, Rumbeiha W, Fitzgerald SD, Stein G, Baek SH, Goudreau J, Kassab M, Majid A]
通讯作者:
Majid A
Preclinical efficacy and toxicity evaluation of carnosine in stroke
-
批准号:7532388
-
项目类别:
-
资助金额:$19.95万
-
财政年份:2008
-
负责人:ARSHAD MAJID
-
依托单位:
海外基金